Received Aug 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
she was diagnosed with shingles/lack of effect/Itching; This non-serious case was reported by a consumer via call center representative and described the occurrence of shingles in a 75-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. In MAR-2025, the patient received the 1st dose of Shingrix. In JUN-2025, between 2 and 3 months after receiving Shingrix, the patient experienced shingles (Verbatim: she was diagnosed with shingles/lack of effect/Itching). The patient was treated with prednisone. The outcome of the shingles was resolved. It was unknown if the reporter considered the shingles to be related to Shingrix. It was unknown if the company considered the shingles to be related to Shingrix. Additional Information: GSK receipt date: 10-JUL-2025 The patient was the reporter. She stated that she had received her first dose of Shingrix in March 2025. In June 2025, she was diagnosed with shingles, indicating a lack of effect. She mentioned that she broke out on one side of her body (location not disclosed) and experienced itching but did not develop a rash, bumps, or lesions. She reported being prescribed an antiviral and Prednisone to take for 10 days (name, frequency, and dose not disclosed). She stated that she had recently finished her course of Prednisone, and her case of shingles appeared to be resolved. She also noted that she did not experience any pain or complications related to this case of shingles. No further information was provided or obtained.